The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
Open Access
- 1 June 2009
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (6) , 964-971
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblastsPathoGenetics, 2008
- Therapeutic Approaches in Glycogen Storage Disease Type II/Pompe DiseaseNeurotherapeutics, 2008
- ENZYME REPLACEMENT THERAPY FOR INFANTILE-ONSET POMPE DISEASE: CURSE OR CURE?Neurology, 2008
- Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe diseaseHuman Mutation, 2008
- Isofagomine increases lysosomal delivery of exogenous glucocerebrosidaseBiochemical and Biophysical Research Communications, 2008
- Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 GangliosidosisJournal of Biological Chemistry, 2007
- Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe DiseaseMolecular Therapy, 2006
- Storage solutions: treating lysosomal disorders of the brainNature Reviews Neuroscience, 2005
- Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycansGlycobiology, 2004
- Pompe disease in infants and childrenThe Journal of Pediatrics, 2004